Table 2.
Influence of CAD on plasma levels of MMP-2, MMP-9, and TIMP-4.
| CAD | Control | p value | CAD + HT − DM− | Control | p value | CCSII | CCSIII | p value | |
|---|---|---|---|---|---|---|---|---|---|
| MMP-2 (ng/ml) | 154.5 ± 51.0 | 165.7 ± 19.1 | 0.037 | 134.5 ± 23.2 | 165.7 ± 19.1 | <0.001 | 154.0 ± 51.6 | 158.8 ± 49.6 | 0.77 |
| MMP-9 (ng/ml) | 46.4 ± 26.4 | 47.2 ± 22.3 | 0.91 | 47.6 ± 29.4 | 47.2 ± 22.3 | 0.97 | 45.5 ± 25.4 | 54.2 ± 34.8 | 0.71 |
| TIMP-4 (pg/ml) | 1621.9 ± 757.4 | 1153.2 ± 339.9 | 0.011 | 1733.0 ± 665.4 | 1153.2 ± 339.9 | 0.008 | 1631.8 ± 788.0 | 1546.1 ± 487.4 | 0.85 |
CAD: coronary artery disease; CAD + HT − DM−: group of patients suffering from coronary artery disease only; CCSII, CCSIII: Canadian Cardiac Society classification of coronary artery disease clinical status: stage II and stage III, respectively; MMP-2: matrix metalloproteinase-2; MMP-9: matrix metalloproteinase-9; TIMP-4: tissue inhibitor of metalloproteinases 4. Mean ± SEM. Statistical tests used: Mann–Whitney U test and unpaired t-test.